Introduction {#s1}
============

Over the past decade, awareness has increased that house dust is a matrix containing complex mixtures of contaminants. Most of these contaminants originate from the use and wear of household products and building materials; indoor activities such as cooking, smoking, and incineration of (household) products; and the intrusion of outdoor material ([@c47]). In an inventory of contaminants reported in house dust, Zhang et al. ([@c82]) found 485 organic compounds, including alkyl-phenols and their ethoxylates, phthalates, parabens, musks, perfluoroalkyl substances (PFASs), brominated flame retardants (BFRs) including polybrominated diphenyl ethers (PBDEs), organophosphorous flame retardants (OPFRs), polychlorinated biphenyls (PCBs), polyhalogenated dibenzo-*p*-dioxins and dibenzofurans (PXDD/Fs) polycyclic aromatic hydrocarbons, chlorinated benzenes, polychlorinated naphthalenes, organo-siloxanes, volatile organic compounds, ultraviolet (UV)-filter related chemicals, biocides, and pesticides.

Indoor exposure to house dust contaminants may occur through inhalation, dermal contact, and ingestion. The importance of the latter route has been mainly demonstrated for PBDEs. The contribution of house dust ingestion to the total PBDE intake in adults appears to be in the same order of magnitude as the contribution of dietary exposure, although estimates differ considerably between countries ([@c6]; [@c32]). More importantly, these studies concluded that house dust ingestion is the major route of PBDE exposure for toddlers, who have lower dietary intake but higher house dust ingestion than adults due to their relatively long residence time on the floor and frequent hand-to-mouth contact. Given the high number of contaminants demonstrated in house dust, it is to be expected that house dust ingestion especially by toddlers may be an underestimated route of human exposure to compounds other than PBDEs ([@c9]).

Many house dust contaminants are known to be thyroid-hormone (TH) disrupting compounds ([@c82]), such as phenols, phthalates, parabens, PFASs, PBDEs, OPFRs, PCBs, PXDD/Fs, UV filters, and biocides. Some of these chemicals have been reported to antagonize thyroid receptor (TR) activity ([@c33]; [@c34]; [@c83]). Others have been shown to activate the nuclear receptors pregnane X receptor (PXR), constitutive androstane receptor (CAR) ([@c37]), or arylhydrocarbon receptor (AhR) ([@c10]), thereby inducing the expression and activity of uridine diphosphate glucuronosyltransferase (UGT) isoforms 1A1 and 1A6 ([@c72]), which are responsible for an increased glucuronidation ([@c66]; [@c77]) and subsequent hepatic clearance ([@c41]) of TH. Still others have been shown to inhibit the sodium iodide symporter (NIS) ([@c22]; [@c79]) or thyroid peroxidase (TPO) ([@c56]), which are involved in TH synthesis. In the present study, we focus on the TH distributor protein transthyretin (TTR) as a target for TH disrupting compounds. Together with TH binding globulin (TBG) and albumin (ALB), TTR is one of the three plasma carrying proteins transporting TH from the thyroid gland to the peripheral (target) tissues. Although triiodothyronine ($T_{3}$) is the actual active form of TH, these distributor proteins have a higher affinity for its precursor thyroxine ($T_{4}$) ([@c68]). Many xenobiotic substances, including house dust contaminants, are capable of competing with $T_{4}$ for binding to TTR ([@c81]; [@c83]). As a consequence, diminished amounts of TTR-bound $T_{4}$ is stored in the blood plasma and correspondingly larger amounts of free $T_{4}$ are available for biliary elimination via hepatic uptake and conjugation, causing a decrease in free and total plasma $T_{4}$ levels, as observed in rodents exposed to TTR-binding compounds ([@c8]; [@c21]). $T_{4}$ deficiency has been implicated in neurodevelopmental effects on cognition in rodents ([@c75]) and humans ([@c35]). Moreover, TTR-binding PCB metabolites were shown to accumulate in blood plasma of laboratory rats ([@c5]), free-ranging polar bears ([@c20]), and human populations ([@c3]; [@c55]) and may ultimately be transported across the placenta where they have been demonstrated in fetal rat brain ([@c44]) and in human cord blood ([@c55]), most likely due to TTR-mediated transport. It cannot be excluded that this transport route also holds for other persistent TTR-binding compounds.

To our knowledge, the contribution of multiple chemicals present in house dust to displacing $T_{4}$ from TTR has not been investigated. Accordingly, the goal of the present study was *a*) to determine the TTR-binding potency of complex mixtures of house dust contaminants representing the composition as found in human blood and in house dust; *b*) to study whether the TTR-binding potency of the complex mixtures could be predicted by weighing the concentration of each individual constituent of the mixture for its TTR-binding potency, according the principle of concentration addition; and *c*) to extrapolate the TTR-binding capacity of the mixtures in an *in vitro* binding assay to *in vivo* inhibition levels of $T_{4}$-TTR binding in human maternal and infant blood.

Altogether, a set of 25 compounds was selected and tested individually for their capacity to bind to TTR in a competitive binding assay. In addition, three different mixtures were reconstituted reflecting the composition of the selected chemicals based on median concentrations reported in house dust, maternal serum, or in serum from cord blood/infants (hereafter referred to as infants). These mixtures were also tested in the TTR-binding assay to confirm that the principle of concentration addition holds for such complex mixtures. In addition, the mixture experiments allowed us to determine a margin of exposure between the actual median mixture concentration in serum from infants and mothers on the one hand and the observed effect levels in the *in vitro* TTR-binding assay on the other hand. More importantly, the *in vitro* TTR-binding potencies of the mixtures were extrapolated to actual *in vivo* TTR-binding potencies in maternal or infant blood, taking into account the binding of TH to the other two plasma distributor proteins, TBG and ALB. As such, the concentrations in human plasma of TTR-binding inhibitors were calculated into predicted effect levels in humans.

Material and Methods {#s2}
====================

Test Compound Selection {#s2.1}
-----------------------

Test compounds were selected based on three different criteria:

1.  The compounds should be present in house dust, or---in the case of metabolites---their parent compound should be present in house dust. To meet this criterion, all selected compounds or their parent compounds should be listed in the inventory of 485 house dust contaminants made by Zhang et al. ([@c82]).

2.  The TTR-binding capacity of the compounds or their metabolites should have been experimentally confirmed. Weiss et al. ([@c81]) compiled a database of 144 compounds capable of competing with TH for TTR-binding. As was to be expected based on structural similarity with TH, many TTR-binding compounds were halogenated phenols (including metabolites of PBDEs, PCBs, and PXDD/Fs), but PFASs and other (mainly halogenated) compounds were also identified as TTR-binders.

3.  Their concentration in dust, maternal serum, or cord blood/infant serum should be known. For compounds meeting the first two criteria, data on median levels in dust, in maternal serum, and in cord blood/infant serum were collected in 2016 from Swedish studies or alternatively European, preferably Nordic, studies reported in the open literature. The selection of Swedish studies was based on the fact that the present study was performed within a Swedish research project called MiSSE (Mixture aSSessment of Endocrine disrupting compounds with emphasis on the TH system). MiSSE has determined concentrations for many house dust contaminants in Swedish household dust. Many of these concentrations were used in the present study. To obtain geographic correspondence between chemical profiles in house dust and human serum, the present study gave preference to the utilization of Swedish, or else Nordic, serum levels.

The set of 25 selected test chemicals consisted of the following compounds: perfluorohexanoic acid (PFHxA), perfluoroheptanoic acid (PFHpA), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnDA), perfluorobutane sulfonic acid (PFBS), perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctane sulfonamide (FOSA), propyl 4-hydroxybenzoate (propylparaben), 4-nonylphenol, pentachlorophenol, 5-chloro-2-(2,4-dichlorophenoxy)phenol (triclosan), tetrabromo-bisphenol-A (TBBPA), 2,4,6-tribromophenol (2,4,6-TBP), 2,2ʹ,4,4ʹ-tetrabromodiphenyl ether (BDE-47) and its metabolites 5-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether (5-OH-BDE-47) and 6-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether (6-OH-BDE-47), 2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether (BDE-99) and its metabolite 6ʹ-OH-2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether (6ʹ-OH-BDE-99), 2,3ʹ,4,4ʹ,5-pentachlorobiphenyl (CB-118) and its metabolite 4-OH-2,3,3ʹ,4ʹ,5-pentachlorobiphenyl (4-OH-CB-107), and 2,2ʹ,4,4ʹ,5,5ʹ-hexachlorobiphenyl (CB-153) and 4-OH-2,2ʹ,3,4ʹ,5,5ʹ,6-heptachlorobiphenyl (4-OH-CB-187). All test compounds, together with their supplier, Chemical Abstract Service number, and median or high-end (i.e., maximum or 95th percentile) concentrations reported in house dust, maternal and infant blood from Nordic countries are listed in Excel Tables S1 and S2. These Tables further specify whether infant concentrations refer to concentrations in cord blood or in children and provide references to the original publications.

Test Solutions and Mixture Reconstitution {#s2.2}
-----------------------------------------

For most of the selected compounds, stock solutions (10 or $100\;\text{mM}$) and subsequent dilution series were prepared in tetrahydrofuran (THF). To test the individual compounds in the bioassay, stock solutions in dimethyl sulfoxide (DMSO) were prepared by the addition of $200\;\mu L$ of DMSO to $200\;\mu L$ of the THF solutions followed by THF evaporation under a gentle nitrogen flow. To reconstitute a mixture, for each individual compound a precalculated volume corresponding to its ultimate molar fraction in the mixtures was taken from the THF stock or its respective dilution. After pooling these THF volumes for all compounds, $500\;\mu L$ of DMSO was added, followed by THF evaporation. Perfluoroalkyl sulfonic acids (PFSAs) were not dissolved in THF, given the polymerization reaction of THF with highly acidic short-chained PFSAs ([@c57]), also observed for PFBSs in this study. Instead, PFSAs were directly dissolved and further diluted in DMSO. During mixture reconstitution, PFSAs (in DMSO) were added last. The ultimate $500\text{-}\mu L$ volume of DMSO added to the mixture was adjusted accordingly. All DMSO stocks of individual compounds and mixtures were further diluted in DMSO for dose--response testing in the bioassay. During mixture reconstitution, all pipetting steps were weighed, allowing the exact determination of the concentrations in the test mixtures. These actual concentrations (see Table S1) based on weights---and not the originally targeted nominal concentrations---were further used in data analyses. Differences between the actual and the targeted molar contributions to the mixture were at maximum 2.2% but were $< 1\%$ in 95% of the cases.

Dust Extraction {#s2.3}
---------------

To determine the contribution of the compounds tested in the present study to the overall TTR-binding potency in house dust, the extract of a well-characterized dust sample, for which many analytical data were available, was tested in the TTR-binding assay. For this purpose, the Standard Reference Material® 2585 (SRM2585) dust sample was purchased from the National Institute of Standards and Technology (NIST) and extracted according to Van den Eede et al. ([@c76]). Briefly, $70\;{mg}$ of dust was extracted three times with an isohexane:acetone 3:1 (vol/vol) mixture by vortexing followed by ultrasonication. After each consecutive extraction, dust was pelleted by centrifugation and the supernatant was pooled. The solvent was evaporated under a gentle nitrogen flow and the extracts were transferred to $200\;\mu L$ of DMSO.

TTR-Binding Assay {#s2.4}
-----------------

The TTR-binding potency of the individual compounds, the reconstituted mixtures, and the SRM2585 extract was tested in a competitive binding assay making use of a fluorescent conjugate of $T_{4}$ and fluorescein 5-isothiocyanate (FITC). The method originally developed by Ren and Guo ([@c60]) was previously transformed into a 96-well plate format ([@c54]) and further modified and optimized ([@c39]) in our laboratory. The FITC-$T_{4}$ conjugate shows high fluorescence when its $T_{4}$ group is bound to TTR. In the presence of competitive TTR-binding compounds, a decrease in bound FITC-$T_{4}$ can be quantified as a decrease in fluorescence, which is due to the intramolecular quenching of the fluorescein group by the free $T_{4}$ group.

The FITC-$T_{4}$ conjugate was synthesized as described by Ren and Guo ([@c60]). Briefly, $0.5\;{mL}$ of $20\text{-}{mg}/{mL}$ FITC was reacted with $1.0\;{mL}$ of $10\text{-}{mg}/{mL}$ $T_{4}$ (both dissolved in a mixture of $9\;{mL}$ pyridine, $1.5\;{mL}$ ultrapure water, and $0.1\;{mL}$ triethylamine) for 1 h at 37°C. The FITC-$T_{4}$ conjugate was consecutively precipitated, centrifuged, washed, centrifuged, redissolved, and purified on a Sephadex® LH20 column. After elution with ultrapure water, the FITC-$T_{4}$ concentration was determined photospectrometrically using a molar extinction coefficient of $\varepsilon = 7.8 \times 10^{4}{\; M}^{- 1}{cm}^{- 1}$ ([@c60]). The FITC-$T_{4}$ solution was aliquoted and stored at $- 80{^\circ}C$.

All TTR-binding experiments were performed in black 96-well polystyrene nonbinding plates (Greiner Bio-One). Given the minimized adsorption to the wall of these well plates, nominal concentrations of FITC-$T_{4}$, TTR, and test compounds could be used in the data analysis as total concentrations of ligand, binding protein, and inhibitor, respectively. All incubations were performed for 2 h at 4°C (on ice) in a final volume of $200\;\mu L$ Tris-HCl buffer (pH 8.0). Fluorescence \[expressed as arbitrary fluorescence units (AFUs)\] was measured at $\lambda_{\text{ex}} = 490\;\text{nm}$ and $\lambda_{\text{em}} = 518\;\text{nm}$.

The dissociation constant $K_{d}$ of the FITC-$T_{4}$-TTR complex was determined in a saturation experiment with a fixed concentration of TTR ($30\;\text{nM}$), various concentrations of FITC-$T_{4}$ (ranging from 0 to $1,000\;\text{nM}$), and no inhibitor. Competitive TTR-binding assays were performed by incubating human TTR ($30\;\text{nM}$) with $110\;\text{nM}$ of FITC-$T_{4}$ in the presence of test compounds, reference compound $T_{4}$, or carrier solvent control (1% DMSO). For each incubation with TTR, a parallel incubation was performed without TTR to correct for background fluorescence of the unbound FITC-$T_{4}$. In the competitive binding experiments, these control incubations were also used to check for possible quenching of FITC-$T_{4}$ fluorescence by the test compounds and for autofluorescence of the test compounds themselves, neither of which was observed. Altogether, on each 96-well plate three different compounds or mixtures were tested in duplicate with and without TTR in a concentration series of seven concentrations and a solvent control. Each compound, each reconstituted mixture, and the SRM2585 dust extract was tested in two independent experiments, except for the reference compound $T_{4}$, which was tested in 21 experiments altogether. All experiments were performed within a period of 4 weeks.

Background Correction {#s2.5}
---------------------

All fluorescence measurements were corrected for protein-independent fluorescence by subtracting the measured fluorescence in the absence of protein from the measured fluorescence in the presence of protein. The obtained corrected fluorescence ($F_{c}$) is directly proportional to the concentration of the protein--ligand complex \[*PL*\] as demonstrated in "S1.2 Corrected fluorescence is proportional to \[PL\]" in the Supplemental Material, based on the basic principles of protein--ligand binding in the presence of a competitive inhibitor described in "S1.1 Basic principles of protein-ligand binding in the presence of a competitive inhibitor."

$K_{d}$ Estimation {#s2.6}
------------------

$F_{c}$ values of the saturation experiment, expressed in AFUs, could consequently be described as a function of the total ligand concentration ($L_{T}$) $$F_{c} = a \times \left\lbrack {PL} \right\rbrack = a \times \frac{\left( {K_{d} + \left\lbrack P_{T} \right\rbrack + \left\lbrack L_{T} \right\rbrack} \right) - \sqrt{\left( {K_{d} + \left\lbrack {P_{T}{\rbrack + \lbrack}L_{T}} \right\rbrack} \right)^{2} - 4 \times \left\lbrack P_{T} \right\rbrack \times \left\lbrack L_{T} \right\rbrack}}{2},$$with *a* being the ratio between $F_{c}$ and \[*PL*\], \[$P_{T}$\] is the total protein concentration (i.e., $\left\lbrack \text{TTR} \right\rbrack = 30\;\text{nM}$), and \[$L_{T}$\] is the total ligand concentration ranging from 0 to $1,000\;\text{nM}$ FITC-T4 in the saturation experiment. Parameters *a* and $K_{d}$ were estimated by nonlinear regression between \[$L_{T}$\] and $F_{c}$. The theory behind [Equation 1](#d1){ref-type="disp-formula"} and its derivation have been described in detail in "S1.3 K~d~ assessment" in the Supplemental Material, based on Neubig ([@c50]).

Concentration--Response Analysis {#s2.7}
--------------------------------

For the competitive binding experiments, the corrected fluorescence measurements were used to fit concentration--response curves and derive the concentration causing 20% and 50% inhibition of TTR-binding by FITC-$T_{4}$ ($\text{IC}_{20}$ and $\text{IC}_{50}$, respectively). Similarly, concentration--response curves with corresponding $\text{IC}_{20}$ and $\text{IC}_{50}$ values were derived for the mixtures, with mixture concentration ($c_{mix}$) being expressed as the total molar concentration of TTR-binding compounds in proportions reflecting their median concentrations in maternal serum, infant serum, and house dust reported in Nordic countries. For the SRM2585 dust extract, concentration--response curves with corresponding $\text{IC}_{20}$ and $\text{IC}_{50}$ values were derived, expressed as the corresponding dust concentration in the assay (in grams of dust per liter).

Concentration--effect data analysis for individual compounds and mixtures was performed by a best-fit approach ([@c69]) where various nonlinear regression models were fitted to the same pooled data set and the model that described data best was selected. In case of a significant inter-study data variation, experiment was included as random factor in the best-fit data analysis (nonlinear mixed effect model (see [@c2] for more detail).

The effects of the reconstituted mixtures were predicted according to the principle of concentration addition (CA) under the assumption of noninteraction between the compounds ([@c19]). The concentration of the mixture causing *x*% inhibition ($ICx_{mix}$) is calculated from the *ICx* for each individual compound *i* ($ICx_{i}$) leading to the same response X and the relative molar contribution $p_{i}$ of each compound *i* to the mixture ([@c17]): $$ICx_{mix} = \left\lbrack {\sum\limits_{i = 1}^{n}\left( \frac{p_{i}}{ICx_{i}} \right)} \right\rbrack^{- 1}.$$

If an *ICx* for the mixture could not be derived due to incomplete regression curves for the individual compounds (i.e., the individual compounds did not reach an *x%* inhibition level; [Figure 1](#f1){ref-type="fig"}), a worst-case range of mixture predictions was estimated according to the dose extrapolation approach for CA predictions ([@c70]). To account for the statistical uncertainty in the CA prediction, a combined Monte-Carlo (MC) and nonlinear regression bootstrap simulation was conducted to establish approximate 95% confidence limits around the predicted mean mixture response. For each compound a distribution of resampled model fits was simulated by parametric bootstrap with resamples drawn from the fitted nonlinear (mixed) effect model ([@c17]), which then was used as input for an MC to generate a distribution of mixture prediction. Differences between predicted and observed mixture effects were deemed statistically significant when the 95% confidence belts of the prediction did not overlap with those of the experimentally observed mixture effects.

![Individual concentration--response curves for the 25 selected test compounds in the FITC-$T_{4}$ TTR-binding assay. (A) Perfluoroalkyl carboxyl acids (PFCA); (B) perfluoroalkyl sulfonic acids (PFSAs) and FOSA; (C) PCBs and PBDEs; (D) PCB metabolites and PBDE metabolites; (E) other phenols and propylparaben. In each panel the concentration--response curve for the natural ligand $T_{4}$ is displayed as a dashed curve (\-\--). Note: 2,4,6,-TBP, 2,4,6-tribromophenol; 4-OH-CB-107, 4-OH-2,3,3ʹ,4ʹ,5-pentachlorobiphenyl; 4-OH-CB-187, 4-OH-2,2ʹ,3,4ʹ,5,5ʹ,6-heptachlorobiphenyl; 5-OH-BDE-47, 5-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; 6-OH-BDE-47, 6-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; 6ʹ-OH-BDE-99, 6ʹ-OH-2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether; BDE-47, 2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; BDE-99, 2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether; CB-118, 2,3ʹ,4,4ʹ,5-pentachlorobiphenyl; CB-153, 2,2ʹ,4,4ʹ,5,5ʹ-hexachlorobiphenyl; FITC, fluorescein 5-isothiocyanate; FOSA, perfluorooctane sulfonamide; PCB, polychlorinated biphenyl; PDBE, polybrominated diphenyl ether; PFBS, perfluorobutane sulfonic acid; PFDA, perfluorodecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxA, perfluorohexanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid; $T_{4}$, thyroxine; TBBPA, tetrabromo-bisphenol-A; TTR, transthyretin.](ehp-128-017015-g001){#f1}

Toxic Unit Summation {#s2.8}
--------------------

Under the assumption of CA, the ratio between the $c_{mix}$ and the concentration of the mixture expected to cause *x*% inhibition ($ICx_{mix}$) is calculated by the method of Toxic Unit (TU) summation: $$TU_{sum} = \frac{c_{mix}}{ICx_{mix}} = \sum\limits_{i = 1}^{n}TU_{i} = \sum\limits_{i = 1}^{n}{\left( \frac{c_{i}}{ICx_{i}} \right),}$$with $c_{i}$ being the concentration of the *i*th compound in the mixture ($c_{mix} = c_{1}\; + \cdots + \; c_{n}$), $TU_{i}$ representing the toxic unit of the *i*th compound ($TU_{i} = c_{i}/ICx_{i}$), and $TU_{sum}$ representing the toxic units summation. If $TU_{sum}$ equals 1, the mixture concentration is expected to produce *x%* inhibition; if it is smaller or greater, the observable inhibition should be smaller or greater, respectively, although no quantitative expectation on the effect size can be provided.

$K_{i}$ Estimation {#s2.9}
------------------

For each individual inhibitor, its $\text{IC}_{20}$ value in the bioassay was converted into a $K_{i}$ value (i.e., the dissociation constant of the inhibitor--TTR complex), according to $$K_{i} = \frac{K_{d} \times \left\lbrack {PL_{20}} \right\rbrack \times IC_{20}}{\left\lbrack L_{20} \right\rbrack \times \left\lbrack {PI_{20}} \right\rbrack} - {\left\lbrack P_{20} \right\rbrack,}$$where \[$PL_{20}$\] is the concentration of protein--ligand complex, which is 20% lower than in the absence of inhibitor, and with \[$L_{20}$\], \[$PI_{20}$\], \[$P_{20}$\] being the corresponding concentrations of free ligand, protein--inhibitor complex, and free protein, respectively. Derivation of [Equation 4](#d4){ref-type="disp-formula"} and estimation of \[$L_{20}$\], \[$PI_{20}$\], and \[$P_{20}$\] are described in detail in "S1.4 Derivation of $K_{i}$ from the IC~x~ determined in the bioassay" in the Supplemental Material, based on Nikolovska-Coleska et al. ([@c51]). The 20% inhibition level was chosen because robust $\text{IC}_{20}$ values could be established for all compounds in the test set.

Similar $K_{i}$ calculations were made for mixtures reflecting median or high-end concentrations in maternal and infant blood from Nordic countries (see Excel Tables S1 and S2). The underlying $\text{IC}_{20}$ values of these mixtures in the bioassay were calculated based on concentration addition ([Equation 2](#d2){ref-type="disp-formula"}) using the molar proportions of the constituents in the different mixtures considered (see Table S2).

Extrapolation to Human Blood {#s2.10}
----------------------------

The degree by which the different inhibitor mixtures inhibit FITC-$T_{4}$ binding to TTR *in vitro* cannot be directly translated into *in vivo* inhibition levels for TTR-$T_{4}$ binding in human blood, because the assay makes use of a fluorescent FITC-$T_{4}$ probe, and not $T_{4}$. Moreover, $T_{4}$ in human blood not only forms a protein--ligand complex with TTR, but also with other proteins, of which TBG and ALB have highest $T_{4}$-binding capacity ([@c68]).

In the absence of inhibitor, three protein--ligand equilibria are in place that determine the degree of $T_{4}$-TTR binding, that is, $$K_{d}P = \frac{\left\lbrack L \right\rbrack \times \left\lbrack P \right\rbrack}{\left\lbrack {PL} \right\rbrack}$$$$K_{d}X = \frac{\left\lbrack L \right\rbrack \times \left\lbrack X \right\rbrack}{\left\lbrack {XL} \right\rbrack}$$$$K_{d}Y = \frac{\left\lbrack L \right\rbrack \times \left\lbrack Y \right\rbrack}{\left\lbrack {YL} \right\rbrack}$$where

1.  \[*L*\] is the concentration of free ligand (i.e., $T_{4}$ in blood);

2.  \[*P*\], \[*X*\], and \[*Y*\] are the concentrations of unbound TTR, TBG, and ALB, respectively;

3.  \[*PL*\], \[*XL*\], and \[*YL*\] are the concentrations of the protein--ligand complex TTR-$T_{4}$, TBG-$T_{4}$, and ALB-$T_{4}$, respectively;

4.  $K_{d}P$, $K_{d}X$, and $K_{d}Y$ are the dissociation constants of the protein--ligand complex for TTR, TBG, and ALB, respectively.

In the presence of inhibitor I, an additional equilibrium reaction is in place for the inhibitor--TTR complex, that is, $$K_{i}P = \frac{\left\lbrack I \right\rbrack \times \left\lbrack P \right\rbrack}{\left\lbrack {PI} \right\rbrack}$$where $K_{i}P$ is the dissociation constant of the protein--inhibitor complex for TTR, and \[*I*\] and \[*PI*\] are the concentrations of the free inhibitor and the inhibitor--TTR complex, respectively.

In addition to these four equilibrium reactions, the following five mass balances are in place: $$\left\lbrack L_{T} \right\rbrack = \left\lbrack L \right\rbrack + \left\lbrack {PL} \right\rbrack + \left\lbrack {XL} \right\rbrack + \left\lbrack {YL} \right\rbrack$$$$\left\lbrack P_{T} \right\rbrack = \left\lbrack P \right\rbrack + \left\lbrack {PL} \right\rbrack + \left\lbrack {PI} \right\rbrack$$$$\left\lbrack X_{T} \right\rbrack = \left\lbrack X \right\rbrack + \left\lbrack {XL} \right\rbrack$$$$\left\lbrack Y_{T} \right\rbrack = \left\lbrack Y \right\rbrack + \left\lbrack {YL} \right\rbrack$$$$\left\lbrack I_{T} \right\rbrack = \left\lbrack I \right\rbrack + \left\lbrack {PI} \right\rbrack$$with \[$X_{T}$\], \[$Y_{T}$\], and \[$I_{T}$\] being the total concentration of ligand TBG, ALB, and inhibitor, respectively. For the known parameters in these equations, estimates for \[$L_{T}$\], \[$P_{T}$\], \[$X_{T}$\], and \[$Y_{T}$\] in pregnant women and infants and for human $K_{d}X$ and $K_{d}Y$ were obtained as mean or median values reported in the literature (see Table S3), whereas estimates for $K_{d}P$ and $K_{i}P$ and for \[$I_{T}$\] in maternal and infant blood were obtained from the present study ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}, respectively). The remaining five unknown parameters (i.e., the free concentrations \[*L*\], \[*P*\], \[*X*\], \[*Y*\], and \[*I*\]) were then estimated by solving the five mass balances after rearrangements of [Equations 9](#d9){ref-type="disp-formula"}--[13](#d13){ref-type="disp-formula"} with [Equations 5](#d5){ref-type="disp-formula"}--[8](#d8){ref-type="disp-formula"}. The actual rearrangements as well as the method for solving the mass balances are described in detail in "S1.5 Extrapolation to human blood -- Solving the five mass balances" in the Supplemental Material.

###### 

Concentration--response regression models for the displacement of FITC-$T_{4}$ from TTR by individual compounds, SRM2585 dust extract, and reconstituted mixtures.

Table 1 has eleven columns. The first column lists compounds. The adjacent columns list RM, beta hat subscript 1, beta hat subscript 2, beta hat subscript 3, beta hat subscript min, beta subscript max, I C subscript 20, 95 percent C I of I C subscript 20, I C subscript 50, and K subscript i. Columns 2 to 7 are titled concentration response function.

  Substance             Concentration--response function[^*a*^](#TF2){ref-type="table-fn"}   $\text{IC}_{20}$ (M)   \[95% CI of $\text{IC}_{20}$\]   $\text{IC}_{50}$ (M)   $K_{i}$ (M)                                                                                                                                                                                                                                    
  --------------------- -------------------------------------------------------------------- ---------------------- -------------------------------- ---------------------- ------------------------------------- --- -------------------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Thyroxine ($T_{4}$)   Logit                                                                $- 14.3$               $- 2.05$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $2.1 \times 10^{–8}$                                     \[$1.8 \times 10^{–8}$, $2.5 \times 10^{–8}$\]                                     $1.0 \times 10^{–7}$                                     $3.2 \times 10^{–8}$[^*c*^](#TF4){ref-type="table-fn"}
  PFHxA                 Logit                                                                $- 13.2$               $- 2.50$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.6 \times 10^{–6}$                                     \[$1.1 \times 10^{–6}$, $2.1 \times 10^{–6}$\]                                     $5.6 \times 10^{–6}$                                     $3.4 \times 10^{–6}$
  PFHpA                 Logit                                                                $- 14.0$               $- 2.36$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $3.0 \times 10^{–7}$                                     \[$2.4 \times 10^{–7}$, $3.8 \times 10^{–7}$\]                                     $1.2 \times 10^{–6}$                                     $6.4 \times 10^{–7}$
  PFOA                  Logit                                                                $- 23.3$               $- 3.91$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $4.9 \times 10^{–7}$                                     \[$3.2 \times 10^{–7}$, $7.4 \times 10^{–7}$\]                                     $1.1 \times 10^{–6}$                                     $1.1 \times 10^{–6}$
  PFNA                  Weibull                                                              $- 11.1$               $- 1.79$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $3.6 \times 10^{–7}$                                     \[$2.9 \times 10^{–7}$, $4.5 \times 10^{–7}$\]                                     $1.1 \times 10^{–6}$                                     $7.7 \times 10^{–7}$
  PFDA                  Weibull                                                              $- 9.28$               $- 1.69$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.7 \times 10^{–6}$                                     \[$1.4 \times 10^{–6}$, $2.2 \times 10^{–6}$\]                                     $5.4 \times 10^{–6}$                                     $3.7 \times 10^{–6}$
  PFUnDA                Logit                                                                $- 15.6$               $- 2.84$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.0 \times 10^{–6}$                                     \[$6.1 \times 10^{–7}$, $1.6 \times 10^{–6}$\]                                     $3.1 \times 10^{–6}$                                     $2.2 \times 10^{–6}$
  PFBS                  Logit                                                                $- 11.2$               $- 2.24$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $2.3 \times 10^{–6}$                                     \[$1.7 \times 10^{–6}$, $3.3 \times 10^{–6}$\]                                     $9.7 \times 10^{–6}$                                     $5.1 \times 10^{–6}$
  PFHxS                 Logit                                                                $- 16.7$               $- 2.63$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.4 \times 10^{–7}$                                     \[$9.7 \times 10^{–8}$, $1.9 \times 10^{–7}$\]                                     $4.6 \times 10^{–7}$                                     $2.8 \times 10^{–7}$
  PFOS                  Weibull                                                              $- 11.8$               $- 1.73$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $8.2 \times 10^{–8}$                                     \[$6.2 \times 10^{–8}$, $1.1 \times 10^{–7}$\]                                     $2.5 \times 10^{–7}$                                     $1.6 \times 10^{–7}$
  FOSA                  Logit                                                                $- 14.6$               $- 2.38$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.9 \times 10^{–7}$                                     \[$1.3 \times 10^{–7}$, $2.7 \times 10^{–7}$\]                                     $7.3 \times 10^{–7}$                                     $4.0 \times 10^{–7}$
  Propylparaben         G.logit I                                                            $- 16.3$               $- 3.18$                         0.454                  0[^*b*^](#TF3){ref-type="table-fn"}   1   $5.5 \times 10^{–6}$                                     \[$3.8 \times 10^{–6}$, $7.2 \times 10^{–6}$\]                                     $1.9 \times 10^{–5}$                                     $1.2 \times 10^{–5}$
  4-Nonylphenol         Weibull                                                              $- 12.7$               $- 2.21$                                                0.433                                 1   $1.8 \times 10^{–6}$                                     \[$1.2 \times 10^{–6}$, $2.7 \times 10^{–6}$\]                                     $1.6 \times 10^{–5}$                                     $3.9 \times 10^{–6}$
  Pentachlorophenol     Logit                                                                $- 18.4$               $- 2.55$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.7 \times 10^{–8}$                                     \[$1.1 \times 10^{–8}$, $2.8 \times 10^{–8}$\]                                     $6.0 \times 10^{–8}$                                     $2.4 \times 10^{–8}$
  Triclosan             Weibull                                                              $- 12.7$               $- 2.08$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $4.4 \times 10^{–7}$                                     \[$3.4 \times 10^{–7}$, $5.9 \times 10^{–7}$\]                                     $1.1 \times 10^{–6}$                                     $9.3 \times 10^{–7}$
  TBBPA                 Weibull                                                              $- 17.0$               $- 2.23$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.4 \times 10^{–8}$                                     \[$1.2 \times 10^{–8}$, $1.8 \times 10^{–8}$\]                                     $3.4 \times 10^{–8}$                                     $1.7 \times 10^{–8}$
  2,4,6-TBP             Logit                                                                $- 20.5$               $- 2.71$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $8.9 \times 10^{–9}$                                     \[$6.9 \times 10^{–9}$, $1.1 \times 10^{–8}$\]                                     $2.9 \times 10^{–8}$                                     $5.5 \times 10^{–9}$
  BDE-47                G.logit II                                                           $- 20.2$               $- 1.07$                         $7.74 \times 10^{5}$   0[^*b*^](#TF3){ref-type="table-fn"}   1   $2.1 \times 10^{–7}$                                     \[$1.4 \times 10^{–7}$, $3.1 \times 10^{–7}$\]                                     $1.3 \times 10^{–6}$                                     $4.4 \times 10^{–7}$
  5-OH-BDE-47           Logit                                                                $- 36.9$               $- 4.87$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.4 \times 10^{–8}$                                     \[$8.7 \times 10^{–9}$, $2.1 \times 10^{–8}$\]                                     $2.7 \times 10^{–8}$                                     $1.6 \times 10^{–8}$
  6-OH-BDE-47           Logit                                                                $- 19.7$               $- 2.8$                                                 0[^*b*^](#TF3){ref-type="table-fn"}   1   $3.1 \times 10^{–8}$                                     \[$2.4 \times 10^{–8}$, $4.2 \times 10^{–8}$\]                                     $9.8 \times 10^{–8}$                                     $5.4 \times 10^{–8}$
  BDE-99                Logit                                                                $- 44.5$               $- 6.29$                                                0.514                                 1   $7.3 \times 10^{–8}$                                     \[$5.6 \times 10^{–8}$, $8.9 \times 10^{–8}$\]                                     ---[^*g*^](#TF8a){ref-type="table-fn"}                   $1.5 \times 10^{–7}$
  6ʹ-OH-BDE-99          Logit                                                                $- 28.3$               $- 3.68$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $8.4 \times 10^{–9}$                                     \[$5.5 \times 10^{–9}$, $1.2 \times 10^{–8}$\]                                     $2.0 \times 10^{–8}$                                     $4.5 \times 10^{–9}$
  CB-118                G.logit I                                                            $- 32.8$               $- 4.72$                         0.209                  0[^*b*^](#TF3){ref-type="table-fn"}   1   $1.6 \times 10^{–7}$                                     \[$1.2 \times 10^{–7}$, $2.0 \times 10^{–7}$\]                                     $5.6 \times 10^{–7}$                                     $3.2 \times 10^{–7}$
  4-OH-CB-107           G.logit I                                                            $- 14.7$               $- 3.71$                         $1.04 \times 10^{5}$   0[^*b*^](#TF3){ref-type="table-fn"}   1   $3.4 \times 10^{–8}$                                     \[$2.5 \times 10^{–8}$, $4.5 \times 10^{–8}$\]                                     $6.8 \times 10^{–8}$                                     $5.9 \times 10^{–8}$
  CB-153                Logit                                                                $- 30.6$               $- 4.45$                                                0.234                                 1   $7.7 \times 10^{–8}$                                     \[$6.3 \times 10^{–8}$, $9.2 \times 10^{–8}$\]                                     $1.8 \times 10^{–7}$                                     $1.5 \times 10^{–7}$
  4-OH-CB-187           Logit                                                                $- 35.4$               $- 4.55$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $8.2 \times 10^{–9}$                                     \[$5.4 \times 10^{–9}$, $1.2 \times 10^{–8}$\]                                     $1.7 \times 10^{–8}$                                     $4.0 \times 10^{–9}$
  SRM2585               Logit                                                                $- 1.19$               $- 2.13$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $6.2 \times 10^{–2}$[^*d*^](#TF5){ref-type="table-fn"}   \[$4.1 \times 10^{–2}$, $8.9 \times 10^{–2}$\][^*d*^](#TF5){ref-type="table-fn"}   $2.8 \times 10^{–1}$[^*d*^](#TF5){ref-type="table-fn"}   NA[^*e*^](#TF6){ref-type="table-fn"}
  Mixtures                                                                                                                                                                                                                                                                                                                                                                                                                 
   Maternal             Logit                                                                $- 18.9$               $- 2.72$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $3.7 \times 10^{–8}$                                     \[$2.5 \times 10^{–8}$, $5.4 \times 10^{–8}$\]                                     $1.8 \times 10^{–7}$[^*f*^](#TF7){ref-type="table-fn"}   $6.7 \times 10^{–8}$
   Infant               Logit                                                                $- 19.2$               $- 2.75$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $3.3 \times 10^{–8}$                                     \[$2.4 \times 10^{–8}$, $4.4 \times 10^{–8}$\]                                     $1.3 \times 10^{–7}$[^*f*^](#TF7){ref-type="table-fn"}   $5.7 \times 10^{–8}$
   House dust           Logit                                                                $- 14.9$               $- 2.50$                                                0[^*b*^](#TF3){ref-type="table-fn"}   1   $3.2 \times 10^{–7}$                                     \[$2.2 \times 10^{–7}$, $4.6 \times 10^{–7}$\]                                     $1.5 \times 10^{–6}$[^*f*^](#TF7){ref-type="table-fn"}   $6.8 \times 10^{–7}$

Note: 2,4,6,-TBP, 2,4,6-tribromophenol; 4-OH-CB-107, 4-OH-2,3,3ʹ,4ʹ,5-pentachlorobiphenyl; 4-OH-CB-187, 4-OH-2,2ʹ,3,4ʹ,5,5ʹ,6-heptachlorobiphenyl; 5-OH-BDE-47, 5-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; 6-OH-BDE-47, 6-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; 6ʹ-OH-BDE-99; 6ʹ-OH-2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether; BDE-47, 2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; BDE-99, 2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether; CB-118, 2,3ʹ,4,4ʹ,5-pentachlorobiphenyl; CB-153, 2,2ʹ,4,4ʹ,5,5ʹ-hexachlorobiphenyl; CI, confidence interval; FITC, fluorescein 5-isothiocyanate; FOSA, perfluorooctane sulfonamide; $\text{IC}_{20}$, 20% inhibitory concentration; $\text{IC}_{50}$, 50% inhibitory concentration; $K_{i}$, protein--inhibitor dissociation constant; NA, not applicable; PFBS, perfluorobutane sulfonic acid; PFDA, perfluorodecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxA, perfluorohexanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid; RM, regression model; SRM2585, Standard Reference Material® 2585 house dust extract; $T_{4}$, thyroxine; TBBPA, tetrabromo-bisphenol-A; TTR, transthyretin.

Mathematical regression model as defined by Scholze et al. ([@c69]): ${\hat{\beta}}_{1},{\hat{\beta}}_{2},{\hat{\beta}}_{3},{\hat{\beta}}_{\min}$ estimated model parameters, given for concentrations expressed in M (rounded values), $\beta_{\max}$ were not estimated, but set to 1 relating to the mean value of the controls.

Held fixed.

The dissociation constant for the TTR-$T_{4}$ complex was determined as a $K_{i}$ value for $T_{4}$ in the competitive binding experiments with ligand FITC-$T_{4}$ and competitor $T_{4}$ but was applied as a $K_{d}$ value for $T_{4}$ in the extrapolation from the *in vitro* bioassay to the *in vivo* situation in human blood.

$\text{IC}_{20}$ and $\text{IC}_{50}$ values for the SRM2585 house dust sample are expressed in g dust/L, not in M.

The $K_{i}$ value for house dust cannot be calculated given that it should be expressed in mol/L, not in g/L.

Derived from the toxic unit extrapolation method by Scholze et al. ([@c70]): the two worst-case toxic unit assumptions resulted into nearly identical estimation and thus are reported only as single value.

50% inhibition level was not reached for BDE-99 (see [Figure 1](#f1){ref-type="fig"}).

###### 

Total concentrations and corresponding TTR-binding potencies of mixtures consisting of median or high-end concentrations determined in maternal and infant serum from Nordic countries as measured in the *in vitro* binding assay and as extrapolated to human blood.

Table 2 has five columns. The first column lists parameters. The adjacent columns list median concentrations and high-end concentrations for maternal mixture and infant mixture.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                                                                                            Maternal mixture based on                        Infant mixture based on                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------
  Total inhibitor concentration in blood (M)                                                                                           $5.1 \times 10^{–8}$                             $2.5 \times 10^{–7}$                             $4.0 \times 10^{–8}$                             $1.3 \times 10^{–7}$

  $\text{IC}_{20}$ predicted in bioassay (M)\                                                                                          $5.7 \times 10^{–8}$\                            $7.3 \times 10^{–8}$\                            $3.9 \times 10^{–8}$\                            $3.1 \times 10^{–8}$\
  (95% confidence interval)                                                                                                            \[$4.2 \times 10^{–8}$, $7.2 \times 10^{–8}$\]   \[$5.3 \times 10^{–8}$, $9.5 \times 10^{–8}$\]   \[$2.7 \times 10^{–8}$, $5.5 \times 10^{–8}$\]   \[$2.1 \times 10^{–8}$, $4.5 \times 10^{–8}$\]

  $\text{TU}_{\text{sum}}$ in blood based on $\text{IC}_{20}$ in bioassay                                                              0.89                                             3.5                                              1.0                                              4.0

  $K_{i}$ (predicted in the bioassay) (M)                                                                                              $1.1 \times 10^{–7}$                             $1.5 \times 10^{–7}$                             $7.1 \times 10^{–8}$                             $5.4 \times 10^{–8}$

  Fraction of TTR in blood occupied by $T_{4}$ (%)                                                                                                                                                                                                                                        

   Without inhibitor mixture                                                                                                           0.11                                             0.11                                             0.085                                            0.085

   With inhibitor mixture                                                                                                              0.10                                             0.099                                            0.084                                            0.081

  Fraction of $T_{4}$ in blood bound to TTR (%)                                                                                                                                                                                                                                           

   Without inhibitor mixture                                                                                                           3.1                                              3.1                                              1.7                                              1.7

   With inhibitor mixture                                                                                                              3.0                                              2.9                                              1.7                                              1.6

  Inhibition in $T_{4}$-TTR binding in blood compared with situation without inhibitor mixture (%)[^*a*^](#TF9){ref-type="table-fn"}   1.3                                              6.2                                              1.5                                              4.9

  $\text{IC}_{20}$ in blood (M)                                                                                                        $8.0 \times 10^{–7}$                             $8.1 \times 10^{–7}$                             $5.2 \times 10^{–7}$                             $5.1 \times 10^{–7}$

  $\text{TU}_{\text{sum}}$ in blood based on $\text{IC}_{20}$ in blood                                                                 0.063                                            0.31                                             0.077                                            0.24

  Margin of exposure to $\text{IC}_{20}$ in blood                                                                                      16                                               3.2                                              13                                               4.1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: All estimates are based on predicted $\text{IC}_{20}$ values calculated according to the principle of concentration addition. The corresponding estimates for the different blood parameters used to make these calculations (i.e., total levels of $T_{4}$, TTR, TBG, ALB, and $K_{d}$ values for the $T_{4}$-TTR, $T_{4}$-TBG, and $T_{4}$-ALB complexes) are provided in Table S3. ALB, albumin; CI, confidence interval; $\text{IC}_{20}$, 20% inhibitory concentration; $K_{i}$, protein--inhibitor dissociation constant; $T_{4}$, thyroxine; TBG, thyroid hormone binding globulin; TTR, transthyretin; $\text{TU}_{\text{sum}}$, Toxic Unit summation.

See [Figure 4](#f4){ref-type="fig"}.

Finally, the inhibition level of $T_{4}$-TTR binding in human blood was determined by comparing the estimated \[*PL*\] in the presence of the inhibitor mixture to the estimated \[*PL*\] in the absence of inhibitor mixture (i.e., $\left\lbrack I_{T} \right\rbrack = 0$).

Contribution of Test Compounds to TTR-Binding Potency of Dust {#s2.11}
-------------------------------------------------------------

For 16 of the 25 compounds tested in this study, a concentration $q_{i}$ (mol/g dust) in the SRM2585 dust sample could be retrieved from the NIST Certificate of Analysis ([@c52]), and from open literature (see Table S4). For each of these 16 compounds, its TTR-binding potency in the FITC-$T_{4}$ binding assay relative to $T_{4}$ was expressed as a relative effect potency ($REP_{i}$) according to $$REP_{i} = \frac{IC20_{T4}}{IC20_{i}}.$$

The combined TTR-binding potency of the 16 contaminants in the SRM2585 sample was expressed as a calculated $T_{4}$-equivalent concentration in dust \[$qT4EQ_{\text{calculated}}$\] (mol/g dust) by $$\left\lbrack {qT4EQ_{\text{calculated}}} \right\rbrack = \sum\limits_{i = 1}^{16}\left( q_{i} \times REP_{i} \right).$$

Upon testing its extract in the FITC-$T_{4}$ binding assay, the TTR-binding potency of the SRM2585 dust sample was expressed as $IC20_{\text{dust}}$, that is, the dust concentration (g dust/L) corresponding to the extract concentration causing 20% inhibition in the assay. $IC20_{\text{dust}}$ was converted into a $T_{4}$-equivalent concentration in dust \[$qT4EQ_{\text{test}}$\] (mol/g dust) according to $$\left\lbrack {qT4EQ_{\text{test}}} \right\rbrack = \frac{IC20_{T4}}{IC20_{\text{dust}}}.$$

Finally, the contribution of the 16 compounds to the overall TTR-binding potency of the SRM2585 extract was determined by comparing \[$qT4EQ_{\text{calculated}}$\] to \[$qT4EQ_{\text{test}}$\].

Results {#s3}
=======

Mixture Composition {#s3.1}
-------------------

To design a mixture that reflects the composition of TTR-binding contaminants in house dust, infant serum, and maternal serum, median concentrations of the test compounds in these three different matrices were collected from the open literature from studies performed in Sweden or alternatively in a European, preferably Nordic, country (see Excel Tables S1 and S2). Median concentrations in house dust could be collected for 18 of the 25 selected compounds (see Excel Table S1). This excluded the five hydroxylated PBDE and PCB metabolites, which are not expected to be found in house dust, and FOSA and nonylphenol, which have been reported in Swedish serum but had very low detection frequency in European house dust. Median concentrations in human serum were collected for 22 compounds, that is, 21 in maternal serum and 20 in infant serum (see Excel Table S1). No median human serum levels could be retrieved for PFHxA, PFUnDA, and PFBS from Swedish, Nordic, or European studies. At the time of performing the literature search, very few studies had actually looked for these PFASs in human serum. Therefore, it was decided to include these three compounds in the dust mixture to address a more complete PFAS exposure profile to humans.

Mixtures reflecting median concentrations in house dust, maternal, and infant serum were dominated by only a few of the test compounds. In fact, $> 80\%$ of the molar mixture composition could be attributed to 2 of 18 compounds in the reconstituted dust mixture (i.e., propylparaben and triclosan), 4 of 21 compounds in the reconstituted maternal serum mixture (i.e., PFHxS, PFOS, pentachlorophenol, and PFOA), and 3 of 20 compounds in the reconstituted infant serum (i.e., PFOS, pentachlorophenol, and PFOA). Compositions of the reconstituted maternal and infant serum mixtures were similar, and differed considerably from the house dust mixture. The exact compositions of the reconstituted mixtures tested in the TTR-binding assay are provided in Table S1.

TTR-Binding by Individual Compounds {#s3.2}
-----------------------------------

From the saturation experiment with $30\;\text{nM}$ TTR and a concentration series of FITC-$T_{4}$, a $K_{d}$ value of $140\;\text{nM}$ was determined for the FITC-$T_{4}$-TTR complex. For all individual test compounds a concentration-dependent displacement of FITC-$T_{4}$ from the TTR protein was observed in the competitive binding experiments ([Figure 1](#f1){ref-type="fig"}), confirming earlier studies with a radioligand binding assay (RLBA) (see Excel Table S1). All concentration--response models as well as the estimates for their $\text{IC}_{20}$, $\text{IC}_{50}$, and $K_{i}$ values are provided in [Table 1](#t1){ref-type="table"}. As was to be expected based on structural similarities with $T_{4}$ and on previously reported RLBA results, 2,4,6-TBP, pentachlorophenol, TBBPA ([Figure 1E](#f1){ref-type="fig"}), and the metabolites of PBDEs and PCBs ([Figure 1D](#f1){ref-type="fig"}) had the highest competitive potency to displace FITC-$T_{4}$ from the TTR protein. In fact, these halogenated phenols all had higher competitive binding potencies than the endogenous ligand $T_{4}$ itself. The PFASs had TTR-binding potencies lower than $T_{4}$ ([Figure 1A,B](#f1){ref-type="fig"}), with the highest potencies found for PFOS. Remarkably, the parent PBDE and PCB compounds also showed competitive binding to TTR, but at high test concentrations the maximum competitive potency of BDE-99 and PCB-153 leveled off before reaching complete inhibition ([Figure 1C](#f1){ref-type="fig"}). In the RLBA, only very weak TTR-binding potency had been observed for the parent PBDE and PCB compounds. Altogether, a Pearson's correlation coefficient of $r = 0.87$ was observed between log-transformed $\text{IC}_{50}$ values determined in the competitive binding assay with FITC-$T_{4}$ (the present study) and log-transformed $\text{IC}_{50}$ values previously reported (see Excel Table S1) for the competitive binding assay with radiolabeled $T_{4}$ (see Figure S1).

TTR-Binding by Reconstituted Mixtures {#s3.3}
-------------------------------------

For all three mixtures, a concentration-dependent decrease in TTR-binding by FITC-$T_{4}$ was observed, reaching 100% displacement at the highest test concentrations ([Figure 2](#f2){ref-type="fig"}). For each mixture, the concentration--response curve fitted on the measured data overlapped with the confidence intervals of the concentration--response curve calculated according to concentration addition, indicating that TTR-binding of complex mixtures can indeed be approximated well by the concentration addition principle.

![Concentration--response curves for the reconstituted mixtures based on the ratio of median concentrations reported in (A) house dust, (B) maternal serum, and (C) infant serum from Nordic countries. The vertical gray bar in plots B and C indicates the mixture concentration reflecting the median concentration of the individual compounds actually detected in maternal or infant blood samples from Nordic countries. Note: CA, concentration addition; CI, confidence interval; FITC, fluorescein 5-isothiocyanate; $T_{4}$, thyroxine; TTR, transthyretin; TU, Toxic Unit.](ehp-128-017015-g002){#f2}

The combined median concentrations actually reported in maternal or infant serum from Nordic countries approached the $\text{IC}_{20}$ determined for the experimentally tested mixtures (i.e., $\text{TU}_{\text{sum}} \approx 1$) ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}; [Table 2](#t2){ref-type="table"}). According to the principle of concentration addition, concentration response curves and corresponding $\text{IC}_{20}$ values were calculated for the nontested mixtures reflecting high-end concentrations in maternal and infant serum. For these mixtures, the combined high-end concentrations exceeded the predicted $\text{IC}_{20}$ in the bioassay by a factor $> 3$ (i.e., $\text{TU}_{\text{sum}} = 3.5$ and $\text{TU}_{\text{sum}} = 4.0$ for the maternal and infant mixture, respectively; [Table 2](#t2){ref-type="table"}).

![Cumulative plots showing the predicted TTR-binding potency of house dust contaminants or their metabolites at median concentrations reported in (A) maternal and (B) infant serum in Nordic countries. Compounds are ranked according to their contribution to the total TTR-binding potency of the mixture, predicted on the basis of the concentration addition principle. The *y*-axes represent the Toxic Unit summation ($\text{TU}_{\text{sum}}$), i.e., the sum of ranked ratios of the compounds' concentration and its $\text{IC}_{20}$ value. Note: 2,4,6,-TBP, 2,4,6-tribromophenol; 4-OH-CB-107, 4-OH-2,3,3ʹ,4ʹ,5-pentachlorobiphenyl; 4-OH-CB-187, 4-OH-2,2ʹ,3,4ʹ,5,5ʹ,6-heptachlorobiphenyl; 5-OH-BDE-47, 5-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; 6-OH-BDE-47, 6-OH-2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; 6ʹ-OH-BDE-99; 6ʹ-OH-2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether; BDE-47, 2,2ʹ,4,4ʹ-tetrabromodiphenyl ether; BDE-99, 2,2ʹ,4,4ʹ,5-pentabromodiphenyl ether; CB-118, 2,3ʹ,4,4ʹ,5-pentachlorobiphenyl; CB-153, 2,2ʹ,4,4ʹ,5,5ʹ-hexachlorobiphenyl; FOSA, perfluorooctane sulfonamide; $\text{IC}_{20}$, 20% inhibitory concentration; PFBS, perfluorobutane sulfonic acid; PFDA, perfluorodecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxA, perfluorohexanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid; TBBPA, tetrabromo-bisphenol-A; TTR, transthyretin.](ehp-128-017015-g003){#f3}

More than 80% of the inhibition caused by the reconstituted house dust mixture could be attributed to 5 of the 18 compounds present in the mixture, that is, triclosan, TBBPA, BDE-99, pentachlorophenol, and 2,4,6-TBP. For the reconstituted maternal and infant serum mixtures this was the case for even fewer compounds, that is, 3 of 21 (pentachlorophenol, PFOS, and PFHXs) and 2 of 20 compounds (pentachlorophenol and PFOS), respectively (see [Figure 3](#f3){ref-type="fig"}).

TTR-Binding by House Dust Extract {#s3.4}
---------------------------------

For the 16 compounds tested in the present study and analyzed in the SRM2585 dust sample, a summarized $T_{4}$-equivalent concentration was calculated of $4.0\;\text{nmol}/g$ dust (see Table S4). In the TTR-binding assay, the SRM2585 extract showed a concentration-dependent displacement of FITC-$T_{4}$, with $\text{IC}20_{\text{dust}} = 0.062$ g dust/L ([Table 1](#t1){ref-type="table"}). Using the $\text{IC}_{20}$ for $T_{4}$ ([Table 1](#t1){ref-type="table"}), the T4EQ concentration of the SRM2585 dust sample was estimated to be $21/0.062 = 340\;\text{nmol}/g$ dust ([Equation 16](#d16){ref-type="disp-formula"}). Consequently, the 16 compounds for which concentrations were available could only explain $4.0/340 = 1.2\%$ of the totally measured TTR-binding potency.

Extrapolation to Human Blood {#s3.5}
----------------------------

Using the dissociation constants for the $T_{4}$-TTR ligand--protein complex ([Table 1](#t1){ref-type="table"}; this study) and for the $T_{4}$-TBG and $T_{4}$-ALB ligand--protein complexes as well as the median or mean total $T_{4}$ levels determined in normal adult, maternal, or infant blood reported in literature (see Table S3), $> 99\%$ of the total $T_{4}$ concentration in human blood was calculated to bind to the TH binding proteins in the absence of inhibitors. The corresponding TTR/TBG/ALB distribution was estimated to be 6/76/18% in normal adult blood. During the first trimester of pregnancy, when the fetus depends completely on the maternal TH supply, the calculated TTR/TBG/ALB distribution in maternal blood shifts in the direction of TBG (i.e., 3/87/10%), due to increased TBG levels and decreased TTR and ALB levels compared with normal levels (see Table S3). Also for infants, the calculated TTR/TBG/ALB distribution is more dominated by TBG than in normal adults (i.e., 4/90/6%), due to higher TBG and lower TTR and ALB concentrations than reported for normal adults (see Table S3).

In maternal blood, the mixture of inhibitors reflecting median concentrations was estimated to cause a 1.3% inhibition in $T_{4}$-TTR binding compared with the uninhibited situation. In infant blood, the median mixture of inhibitors was estimated to cause a 1.5% inhibition in $T_{4}$-TTR binding ([Table 2](#t2){ref-type="table"}; [Figure 4](#f4){ref-type="fig"}). At high-end inhibitor concentrations, 6.2% inhibition was estimated in maternal blood and 4.9% in infant blood. Consequently, the median or high-end concentrations in maternal or infant blood were lower than the inhibitor concentrations expected to cause 20% *in vivo* inhibition in human blood (i.e., $\text{TU}_{\text{sum}} < 1$), but margins of exposure were small, ranging from 13 to 16 for median concentrations and from 3.2 to 4.1 for high-end concentrations ([Table 2](#t2){ref-type="table"}).

![Estimated concentration--response curves in human blood for mixtures representing median concentrations or high-end concentration of house dust contaminants reported in human (A) maternal or (B) infant serum from Nordic countries. The vertical dashed lines indicate the actual median (left) and high-end (right) concentration found in serum, and the corresponding horizontal dashed lines indicate the concentration of the TTR-$T_{4}$ complex (top and bottom represent median and high-end respectively). The black arrows indicate the $\text{IC}_{20}$ level estimated for serum, which overlap for the two dose--response curves in both panels, i.e., $8.0 \times 10^{–7}\, M$ (median) and $8.1 \times 10^{–7}\, M$ (high-end) for the maternal mixtures and $5.2 \times 10^{–7}\, M$ (median) and $5.1 \times 10^{–7}\, M$ (high-end) for the infant mixtures ([Table 2](#t2){ref-type="table"}). $\text{IC}_{20}$, 20% inhibitory concentration; $T_{4}$, thyroxine; TTR, transthyretin.](ehp-128-017015-g004){#f4}

Discussion {#s4}
==========

The goal of the present study was to determine the TTR-binding potency of reconstituted mixtures of house dust contaminants as present in maternal serum, infant serum, and house dust. In addition, we investigated whether this potency could be predicted according to the principle of concentration addition. Similar TTR-binding potencies were observed for the mixtures reflecting median concentrations in maternal and infant serum in terms of $\text{IC}_{20}$ values (37 and $33\;\text{nM}$, respectively), $\text{IC}_{50}$ values (180 and $130\;\text{nM}$), and corresponding $K_{i}$ values (67 and $57\;\text{nM}$). The house dust mixture was less potent (i.e., $\text{IC}_{20} = 320\;\text{nM}$, $\text{IC}_{50} = 1.5\;\mu M$, $K_{i} = 680\;\text{nM}$), due to differences in composition between both serum and house dust mixtures (see Table S1).

A major part (i.e., $> 80\%$) of the observed inhibition of FITC-$T_{4}$ binding to TTR could be attributed to a minor part (i.e., $< 20\%$) of the compounds present in the mixture. These results support Pareto's principle that 80% of the outcome can be explained by only 20% (or less) of the causal factors. Similar results were previously found in an androgen-receptor (AR) antagonistic reporter gene assay with mixtures consisting of 22 anti-androgenic compounds that were reconstituted according to their proportion in average and high-end serum levels ([@c36]). In our TTR-binding assay, pentachlorophenol and TBBPA were driving compounds (i.e., explaining a significant amount of the observed TTR-binding capacity) in all three mixtures. Some compounds, however, were driving the TTR-binding potency in one reconstituted mixture but not in the other, like PFOS in both human serum mixtures, PFHxS and 4-OH-CB-187 more particular in the maternal serum mixture, and triclosan and propylparaben in the house dust mixture.

For the mixtures based on median blood levels, the actual median concentrations in blood were in the same range as the corresponding $\text{IC}_{20}$ values determined in the bioassay (i.e., $\text{TU}_{\text{sum}} \approx 1$). In previous studies, the OH-PBDEs in blood from children working on Nicaraguan e-waste sites were estimated to contain TTR-binding potency equivalent to $0.55\;\text{nM}$ $T_{4}$ ([@c23]). Similarly, the PFAS compounds in blood from European and North American adults were estimated to have TTR-binding potency equivalent to 3.1 and $5.1\;\text{nM}$ $T_{4}$, respectively ([@c80]). Given the $\text{IC}_{20}$ of approximately $30\;\text{nM}$ determined for $T_{4}$ in the radioligand binding assay used in these studies, the observed $T_{4}$ equivalent concentrations correspond to $\text{TU}_{\text{sum}} = 0.018$ for OH-PBDEs and to $\text{TU}_{\text{sum}} = 0.10$ to 0.17 for PFAS. These values are very much in line with the contribution of these compounds to the overall TTR-binding capacity determined in the present study ([Figure 3](#f3){ref-type="fig"}).

The mixtures reflecting actual high-end concentrations in maternal and infant blood exceeded the $\text{IC}_{20}$ predicted for the bioassay by a factor of 3.5 and 4.0, respectively. The relatively small difference in toxic potencies between the median and the high-end concentration mixtures is due to the fact that no maximum concentrations were reported for many compounds. Instead, we used the 95th percentile from reported serum concentrations as a proxy for the maximum concentration, which implies that 5% of the population is expected to have even higher serum concentrations. For the PFAS compounds, high-end concentrations in maternal serum were estimated using a conservative ratio between the maximum and an average level of 3, based on PFAS measurements in a Spanish study ([@c43]). Altogether, ratios between high-end and median concentrations for most TTR-binding compounds ranged from $< 2$ to 10, except for triclosan (both maternal and infant); PFHxS, PFOS, and TBBPA (infant); and propylparaben (maternal) (see Excel Tables S1 and S2).

The finding that median concentrations in blood correspond to $\text{IC}_{20}$ levels in the bioassay cannot be directly translated to the actual *in vivo* inhibition of $T_{4}$-TTR binding in human blood at similar inhibitor concentrations. After all, the bioassay makes use of a fluorescent-labeled FITC-$T_{4}$ probe (and not $T_{4}$ itself), which is tested in an overdose (i.e., $\left\lbrack {\text{FITC-}T_{4}} \right\rbrack = 110\;\text{nM}$) compared with the only TH binding protein present in the assay (i.e., $\left\lbrack \text{TTR} \right\rbrack = 30\;\text{nM}$). Under physiological conditions, $T_{4}$ is indeed present at similar concentrations as FITC-$T_{4}$ in the assay, but TTR is complemented by two other $T_{4}$-binding proteins (i.e., TBG and ALB), whereas all three $T_{4}$-binding proteins are present at much higher concentrations than the TTR concentration in the bioassay \[see Table S3). Using values from the literature for $T_{4}$ concentration and dissociation constants, \[i.e., $\left\lbrack T_{4} \right\rbrack = 107\;\text{nM}$, $K_{d}\left( \text{TTR} \right) = 14.3$, $K_{d}\left( \text{TBG} \right) = 0.100$, $K_{d}\left( \text{ALB} \right) = 1,430\;\text{nM}$ ([@c68])\], a 12/71/17% distribution of $T_{4}$ over TTR/TBG/ALB was calculated. This distribution is very similar to the 11/74/15% distribution calculated by Schussler ([@c71]) based on free $T_{4}$ rather than total $T_{4}$ concentrations and to the 15/75/10% distribution traditionally believed to be present in blood (e.g., [@c61]), although it is unclear whether this latter distribution was actually calculated or measured. Using the dissociation constant determined in the present study for the TTR-$T_{4}$ complex (i.e., $K_{d} = 32\;\text{nM}$; [Table 1](#t1){ref-type="table"}), however, the distribution of $T_{4}$ over TTR/TBG/ALB in blood was calculated to be 6/76/18%. The difference between both dissociation constants for the TTR-$T_{4}$ complex reported in the literature and determined in the present study may be due to differences in experimental temperatures, that is, 37°C ([@c65]) and 4°C (the present study), although temperature did not seem to affect the $T_{4}$ binding in our binding assay (see Figure S2). The 4°C temperature was chosen in order to resemble previous studies with radioligand binding assays performed at this temperature (e.g., [@c23]; [@c80]; [@c82]). Alternatively, the difference may be explained by the different methods used to establish the dissociation constant. Although the method used to determine the $K_{d} = 14.3\;\text{nM}$ is not clear, it must be different from the method used in the present study given that the fluorescent FITC-$T_{4}$ probe was not described before 2012 ([@c60]). Still, both $K_{d}$ values fit very well within the span of other $K_{d}$ values reported in the literature ranging from $K_{d} = 5\;\text{nM}$ determined at unknown temperature ([@c18]) to $K_{d} = 84\;\text{nM}$ determined at 25°C ([@c58]). Therefore, we have used the $K_{d}$ value determined in the present study to estimate the *in vivo* inhibition for the human situation. Thus, the dissociation constant for the TTR-$T_{4}$ complex was directly comparable to the dissociation constant for the inhibitor--TTR complex determined at the same temperature (4°C).

Using these latter dissociation constants (i.e., $K_{i}$ values), $T_{4}$-binding to TTR in blood was estimated to be inhibited by 1.3--1.5% by the mixture of house dust contaminants at median concentration levels ([Table 2](#t2){ref-type="table"}). The relevance of this $T_{4}$ displacement from TTR in humans remains to be clarified. For the majority of the TTR-binding compounds considered in the present study, rodent studies have found a decrease in circulating total $T_{4}$ levels in serum or plasma (see, for instance, reviews by [@c11], [@c13], [@c12], [@c14]). The decrease is attributed to the fact that $T_{4}$ displaced from TTR is freely available for hepatic uptake and conjugation followed by biliary elimination. This increased hepatic clearance is further enhanced by the fact that many of the test compounds can activate nuclear CAR and PXR receptors, causing an induction of hepatic phase II enzymes responsible for glucuronidation or sulfation of $T_{4}$. Animal studies with PBDEs, PCBs, and PFASs have further indicated that decreased maternal levels of circulating $T_{4}$ are associated with neurodevelopmental effects on cognitive function, motor activity, and behavior in offspring ([@c11], [@c13], [@c12], [@c14]). In humans, however, the situation is less clear. For the compounds considered in the present study, some studies have reported negative associations with $T_{4}$ levels in blood ([@c31]; [@c42]; [@c85]; [@c86]), but other studies have reported positive associations ([@c12]; [@c73]; [@c74]), concentration-dependent associations ([@c84]), or a lack of associations ([@c4]; [@c30]; [@c53]). The observed difference between rodent and human studies is attributed to the fact that humans have a reserve of $T_{4}$ stably bound to TBG. In rodents, however, TBG is not found at the age they are usually tested for in animal studies ([@c40]; [@c78]). As a consequence, rodents have a faster $T_{4}$ turnover than humans \[half-life times of 12--24 h compared with 5--9 d, respectively ([@c27])\] and are considered to be more sensitive than humans to changes in TH balance by $T_{4}$ displacement from TTR or by induced hepatic clearance.

The higher binding affinity of $T_{4}$ for TBG than for TTR and ALB, which is also reflected by the TTR/TBG/ALB binding proportions calculated above, could be taken to suggest that TTR-binding in human blood is much less important than TBG-binding. This suggestion, however, is too simplistic because the actual relevance of TTR-binding is most likely not in the circulation of $T_{4}$ but in the delivery of free $T_{4}$ hormone to the target cells, which depends on the dissociation rate ($k_{\text{off}}$) of the TTR-$T_{4}$ complex and the capillary transit time ([@c61]). The dissociation rates for $T_{4}$ from the different TH binding proteins range from $k_{\text{off}} = 0.017{\; s}^{- 1}$ for TBG, via $k_{\text{off}} = 0.080{\; s}^{- 1}$ for TTR, to $k_{\text{off}} > 0.5{\; s}^{- 1}$ for ALB ([@c46]). Given the capillary transit time in different tissues ([@c45]), the contribution of the TTR-$T_{4}$ complex to the free $T_{4}$ pool equals that of the TBG-$T_{4}$ complex ([@c64]). As such, the late Sidney Ingbar, a specialist in thyroid endocrinology, considered TBG as the saving account for $T_{4}$ and TTR as the checking account ([@c64]). In the same context, others drew a parallel to the Goldilocks principle, that is, TBG binds $T_{4}$ too tightly for delivery of free $T_{4}$ to target cells, ALB binds $T_{4}$ too loosely, and TTR binds $T_{4}$ just right ([@c1]). Consequently, inhibition of TTR-$T_{4}$ binding by xenobiotic compounds may interfere with the level of $T_{4}$ delivery at the target tissue.

TTR is also known to play a role in the $T_{4}$ transport across at least two barriers in distribution, that is, the placenta and the blood-cerebrospinal-fluid barrier (BCSFB) ([@c38]; [@c63]). Both barriers are known to synthesize endogenous TTR. After excretion into the maternal blood circulation (i.e., apical side), placental TTR binds $T_{4}$ upon which the TTR-$T_{4}$ complex passes the placenta and is thought to be finally delivered at the fetal capillaries ([@c38]). TTR produced by the choroid plexus epithelial cells is not excreted to the blood-facing (basolateral) side but, rather, binds intracellularly to the $T_{4}$ taken up by the cells and is then excreted into the cerebrospinal fluid, where it is distributed to the brain ([@c63]). This transcellular route across the BCSFB seems especially relevant for TH transport to the developing brain ([@c29]). The possible effect of TTR-binding xenobiotic compounds on the transport of TH across these barriers is a subject for further studies. In our opinion, such studies should also include the transport of the TTR-binding xenobiotics across these barriers.

Despite TTR's role in the delivery of TH at the target tissue, and the transport of TH across the barriers, an association between maternal TTR malfunctioning and neurodevelopmental disorders in children and infants has not been reported. TTR mutations in humans have been associated with peripheral neuropathy due to amyloid deposition ([@c28]) but not to effects on the developing brain due to TH deficiency. On the other hand, no humans lacking TTR have been reported either. This suggests that TTR's role in transporting sufficient TH to the developing fetal brain is crucial for survival. This hypothesis, however, was questioned when Episkopou et al. ([@c15]) demonstrated that TTR-null mice were viable, fertile, and without an overt TH-deficient phenotype. Apparently, the absence of TTR-mediated TH transport to the developing fetal brain was compensated by transmembrane transporter proteins such as monocarboxylate transporters (e.g., Mct8) and organic anion transporting polypeptides (e.g., Oatp1c1). More recent studies, however, did report differences in brain development between TTR-null and wild-type mice, that is, a decrease in TH-dependent apoptosis of neural stem cells in the subventricular zone ([@c62]) and a delay in TH-regulated events in central nervous system maturation ([@c48]). It is not known whether such effects also occur in humans and whether they affect cognition in children and infants.

The predictive value of the estimated 1.3--1.5% inhibition of $T_{4}$-binding to TTR in human blood by house dust contaminants at median concentration levels needs to be further put in perspective. So far, inhibitor binding to other proteins than TTR is not considered simply because no $K_{i}$ values for other proteins are available. Inhibitor binding to other proteins may decrease the concentration of free inhibitor and thereby its bioavailability to compete with $T_{4}$ for TTR binding. On the other hand, the inhibitors may also bind to TBG and ALB and thereby compete for their $T_{4}$-binding capacity. The consequence of such binding for $T_{4}$ binding in general and for $T_{4}$ delivery by TTR can only be estimated if $K_{i}$ values become available for the TBG-inhibitor and ALB-inhibitor complexes.

Furthermore, many TTR-binding house dust contaminants are not represented in the mixtures studied in the present paper, because their presence in house dust or human blood is unknown or because their TTR-binding potency is unknown. As shown for the SRM2585 house dust sample, the 16 PFAS, PBDE, PCB and halogenated phenolic compounds for which concentrations were available only contributed 1.2% to the overall TTR-binding potency of the house dust extract. This finding clearly illustrates that house dust contains many more TTR-binding compounds than we currently know. Similarly, Kollitz et al. ([@c34]) demonstrated that house dust extracts significantly antagonized activation of the TH receptor $\beta\;\left( {\text{TR}\beta} \right)$ by $T_{3}$. $\text{TR}\beta$ antagonistic activity was negatively associated with free $T_{4}$ levels in residents from the sampled houses and positively correlated with the presence of 12 brominated or organophosphorus flame retardants in the house dust. Because all 12 contaminants were inactive as $\text{TR}\beta$ antagonists on an individual basis, these results suggest either a synergistic mechanism or the presence of unknown $\text{TR}\beta$ antagonistic contaminants in house dust co-occurring with the 12 flame retardants. Previous nontargeted screening studies ([@c59]; [@c67]) have confirmed that house dust contains thousands of chemicals of which the identity is unknown, let alone their TH disrupting capacity. Still, the different patterns in major contributors to the TTR-binding potencies in the mixtures reflecting known TTR-binding compounds in human blood and house dust indicate that dust is not the only route of human exposure to TTR-binding compounds. Most likely, exposure through food also contributes significantly to levels of TTR-binding compounds in human blood.

Moreover, the present study focused on mixtures reflecting median serum concentrations in Nordic countries. Especially for PBDEs, it is well known that serum levels are 4--18 times higher in North American than in European populations ([@c7]; [@c25]; [@c26]). The contribution of the PBDEs and their metabolites to the TTR-binding potency of the reconstituted serum mixtures tested in the present study, however, was negligible ([Figure 3](#f3){ref-type="fig"}). This finding did not change if concentrations of PBDEs and their metabolites were multiplied by a worst-case factor of 20. Given the fact that regional differences in serum concentrations are less obvious for the other compounds included in the present study, the results obtained for the Nordic mixtures are expected to be representative for other regions as well.

As discussed above, no clear relationship has been found between exposure to TTR-binding compounds and circulating $T_{4}$ levels in humans. This may be due to the relatively small predicted effect size at median exposure levels, that is, 1.3--1.5% inhibition of $T_{4}$-TTR binding ([Table 2](#t2){ref-type="table"}). Similarly, Audet-Delage et al. ([@c4]) found that concentrations of TTR-binding compounds in Inuit women of childbearing age were not high enough to affect TTR-mediated TH transport. Although this study population was considered to have a relatively high dietary exposure to persistent organic pollutants including PCBs, PBDEs, PFASs, and pentachlorophenol, the reported plasma concentrations of TTR-binding compounds in the Inuit women were in the same range (i.e., PFOSs) or lower (i.e., OH-CBs and pentachlorophenol) than the median concentrations in Nordic countries used for reconstituting the median exposure level mixture in the present study. Given the between-day variation in their TTR (11.9%) and $T_{4}$-TTR (19.7%) measurements ([@c4]), it is to be expected that a predicted effect size in the same range or lower than in the present study (i.e., 1.3% inhibition in $T_{4}$-TTR binding in maternal blood; [Table 2](#t2){ref-type="table"}) could not be detected in the Inuit women. We expect, however, that the absolute decrease in $T_{4}$-TTR binding corresponding to a relative decrease of 1.3--1.5% may have more impact on circulating TH levels in humans with low $T_{4}$ levels than in humans with normal $T_{4}$ levels. As such, we hypothesize that the presence of TTR-binding house dust contaminants in blood may especially aggravate the poor TH status in mothers with or prone to developing hypothyroidism or hyperthyroxinemia during early pregnancy, which is associated with impaired neurodevelopment in their offspring ([@c16]; [@c24]; [@c35]; [@c49]).

In conclusion, the TTR-binding potency of reconstituted mixtures of house dust contaminants was well described according to the principle of concentration addition. Moreover, it followed Pareto's principle as $> 80\%$ of the observed inhibition could be explained by $< 20\%$ of the compounds present in the mixture. Based on the observed bioassay responses, the median concentrations of house dust contaminants reported in maternal and infant human serum in Nordic countries were estimated to cause a 1.3--1.5% inhibition in $T_{4}$-TTR binding in human blood. In the high-end concentration range, these estimates even reached 4.9--6.2% inhibition levels. This lack in margin of exposure toward TTR-inhibiting concentrations in blood is unfavorable given the role of TTR in delivery of TH to target tissues and its role in assisting TH to cross the placenta and the BCSFB. Possibly, the estimated inhibition levels may especially have impact on the developing fetal brain in cases of maternal hypothyroidism or hypothyroxinemia.

Supplementary Material
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

The MiSSE project (<https://www.aces.su.se/misse/>) was funded by the Swedish Research Council FORMAS (project 210-2012-131). The authors acknowledge Å. Bergman (Stockholm University) for the initial coordination of the MiSSE project, M. Lamoree (Vrije Universiteit Amsterdam), and J. Kamstra (Vrije Universiteit Amsterdam, currently Utrecht University) for adopting and optimizing the FITC-$T_{4}$ TTR-binding assay in our laboratory, and J. Norrgran Engdahl (Stockholm University) for supporting the compilation of the mixtures.

Supplemental Material is available online (<https://doi.org/10.1289/EHP5911>).

The authors declare they have no actual or potential competing financial interests.

**Note to readers with disabilities:** *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](http://ehp.niehs.nih.gov/accessibility/) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact <ehponline@niehs.nih.gov>. Our staff will work with you to assess and meet your accessibility needs within 3 working days.
